keyword
MENU ▼
Read by QxMD icon Read
search

bcnu

keyword
https://www.readbyqxmd.com/read/28040063/pivotal-role-of-glutathione-depletion-in-enos-uncoupling-of-lps-treated-huvecs
#1
L Chen, E Liu, D Cao, S Li, C Xiao, M Xiong, Q Kou
The present study investigated the relationship between uncoupling of endothelial nitric oxide synthase (eNOS) and vascular endothelial cell (VEC) oxidative stress (OS) during sepsis and the role of eNOS glutathionylation in eNOS uncoupling of septic VECs. Human umbilical vein endothelial cells (HUVECs) cultured in vitro (EA.hy269 cell line) were incubated with Dulbecco's modified Eagle's medium (DMEM) (normal control group), lipopolysaccharide (LPS) (sepsis group), 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) (glutathionylation group), and LPS+ dithiothreitol (DTT) (deglutathionylation sepsis group)...
November 30, 2016: Cellular and Molecular Biology
https://www.readbyqxmd.com/read/28011985/beeam-conditioning-with-bendamustine-replacing-bcnu-before-autologous-transplantation-is-safe-and-effective-in-lymphoma-patients
#2
Stefanie Gilli, Urban Novak, Behrouz Mansouri Taleghani, Gabriela M Baerlocher, Kurt Leibundgut, Yara Banz, Thilo Zander, Daniel Betticher, Thomas Egger, Daniel Rauch, Thomas Pabst
BEAM with BCNU is commonly used for conditioning treatment followed by autologous stem cell transplantation (ASCT). However, pulmonary toxicity and availability issues associated with BCNU prompted us to evaluate bendamustine-replacing BCNU (BeEAM). We analyzed 39 lymphoma patients receiving BeEAM conditioning with 200 mg/m(2) bendamustine at days -7 and -6. The median duration until neutrophil recovery was 11 days, and 15 days for platelet recovery (>20 g/L). The most common grade 3/4 non-hematologic toxicities comprised mucosal side effects (27 pts...
December 24, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/28008595/defective-expression-of-apoptosis-related-molecules-in-multiple-sclerosis-patients-is-normalized-early-after-autologous-haematopoietic-stem-cell-transplantation
#3
G L V de Oliveira, A F Ferreira, E P L Gasparotto, S Kashima, D T Covas, C T Guerreiro, D G Brum, A A Barreira, J C Voltarelli, B P Simões, M C Oliveira, F A de Castro, K C R Malmegrim
Defective apoptosis might be involved in the pathogenesis of multiple sclerosis (MS). We evaluated apoptosis-related molecules in MS patients before and after autologous haematopoietic stem cell transplantation (AHSCT) using BCNU, Etoposide, AraC and Melphalan (BEAM) or cyclophosphamide (CY)-based conditioning regimens. Patients were followed for clinical and immunological parameters for 2 years after AHSCT. At baseline, MS patients had decreased proapoptotic BAD, BAX and FASL and increased A1 gene expression when compared with healthy counterparts...
November 7, 2016: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/27984652/a-multi-institutional-analysis-of-peritransplantation-radiotherapy-in-patients-with-relapsed-refractory-hodgkin-lymphoma-undergoing-autologous-stem-cell-transplantation
#4
Sarah A Milgrom, Shekeab Jauhari, John P Plastaras, Yago Nieto, Bouthaina S Dabaja, Chelsea C Pinnix, Grace L Smith, Pamela K Allen, J Nicholas Lukens, Amit Maity, Yasuhiro Oki, Michelle A Fanale, Sunita D Nasta
BACKGROUND: No consensus exists regarding the use of radiotherapy (RT) in conjunction with high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) for patients with relapsed/refractory classical Hodgkin lymphoma (HL). The objectives of the current study were to characterize practice patterns and assess the efficacy and toxicity of RT at 2 major transplantation centers. METHODS: Eligible patients underwent HDC/ASCT from 2006 through 2015 using the combination of either carmustine (BCNU), etoposide, cytarabine, and melphalan (BEAM) or cyclophosphamide, BCNU, and etoposide (CBV)...
December 16, 2016: Cancer
https://www.readbyqxmd.com/read/27920506/polifeprosan-20-3-85-carmustine-slow-release-wafer-in-malignant-glioma-patient-selection-and-perspectives-on-a-low-burden-therapy
#5
REVIEW
Lawrence Kleinberg
Polifeprosan 20 with carmustine (GLIADEL(®)) polymer implant wafer is a biodegradable compound containing 3.85% carmustine (BCNU, bischloroethylnitrosourea) implanted in the brain at the time of planned tumor surgery, which then slowly degrades to release the BCNU chemotherapy directly into the brain thereby bypassing the blood-brain barrier. Carmustine implant wafers were demonstrated to improve survival in randomized placebo-controlled trials in patients undergoing a near total resection of newly diagnosed or recurrent malignant glioma...
2016: Patient Preference and Adherence
https://www.readbyqxmd.com/read/27845303/new-insights-into-estrogenic-regulation-of-o-6-methylguanine-dna-methyltransferase-mgmt-in-human-breast-cancer-cells-co-degradation-of-er-%C3%AE-and-mgmt-proteins-by-fulvestrant-or-o-6-benzylguanine-indicates-fresh-avenues-for-therapy
#6
Ameya Paranjpe, Nathan I Bailey, Santhi Konduri, George C Bobustuc, Francis Ali-Osman, Mohd A Yusuf, Surendra R Punganuru, Hanumantha Rao Madala, Debasish Basak, Agm Mostofa, Kalkunte S Srivenugopal
Endocrine therapy using estrogen receptor-α (ER-α) antagonists for attenuating horm2one-driven cell proliferation is a major treatment modality for breast cancers. To exploit any DNA repair deficiencies associated with endocrine therapy, we investigated the functional and physical interactions of ER-α with O(6)-methylguanine DNA methyltransferase (MGMT), a unique DNA repair protein that confers tumor resistance to various anticancer alkylating agents. The ER-α -positive breast cancer cell lines (MCF-7, T47D) and ER- negative cell lines (MDAMB-468, MDAMB-231), and established inhibitors of ER-α and MGMT, namely, ICI-182,780 (Faslodex) and O(6)-benzylguanine, respectively, were used to study MGMT- ER interactions...
September 2016: Journal of Biomedical Research
https://www.readbyqxmd.com/read/27758718/current-and-future-drug-treatments-for-glioblastomas
#7
Shigeo Ohba, Yuichi Hirose
Glioblastomas are the most aggressive of all gliomas and have the worst prognosis, with 5-year survival rates of less than 10%. Temozolomide (TMZ) is a DNA-methylating agent. Now that TMZ is available, the standard treatment is to resect as much of the tumor as possible without inducing unacceptable neurologic deficits, followed by treatment with radiation and TMZ. TMZ has also been used for maintenance therapy. Recently, bevacizumab, which is a monoclonal antibody to vascular endothelial growth factor, has been used for the initial treatment of glioblastomas and for the treatment of recurrent glioblastomas...
October 14, 2016: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/27757721/outcome-of-patients-affected-by-newly-diagnosed-glioblastoma-undergoing-surgery-assisted-by-5-aminolevulinic-acid-guided-resection-followed-by-bcnu-wafers-implantation-a-3-year-follow-up
#8
Alessandro Della Puppa, Giuseppe Lombardi, Marta Rossetto, Oriela Rustemi, Franco Berti, Diego Cecchin, Marina Paola Gardiman, Giuseppe Rolma, Luca Persano, Vittorina Zagonel, Renato Scienza
The purpose of the study was to evaluate the clinical outcome of the association of BCNU wafers implantation and 5-aminolevulinic acid (5-ALA) fluorescence in the treatment of patients with newly diagnosed glioblastoma (ndGBM). Clinical and surgical data from patients who underwent 5-ALA surgery followed by BCNU wafers implantation were retrospectively evaluated (20 patients, Group I) and compared with data of patients undergoing surgery with BCNU wafers alone (42 patients, Group II) and 5-ALA alone (59 patients, Group III)...
October 18, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27699999/outpatient-administration-of-beam-conditioning-prior-to-autologous-stem-cell-transplantation-for-lymphoma-is-safe-feasible-and-cost-effective
#9
Robin M Reid, Andrea Baran, Jonathan W Friedberg, Gordon L Phillips, Jane L Liesveld, Michael W Becker, Lucy Wedow, Paul M Barr, Laurie A Milner
High-dose BEAM chemotherapy (BCNU, etoposide, Ara-C, and melphalan) followed by autologous hematopoietic stem cell transplantation is frequently used as consolidative therapy for patients with recurrent or refractory Hodgkin or non-Hodgkin lymphoma. The BEAM regimen has traditionally been administered over 6 days in the hospital, with patients remaining hospitalized until hematologic recovery and clinical stability. In an effort to reduce the length of hospitalization for these patients, our institution has transitioned from inpatient (IP) to outpatient (OP) administration of BEAM conditioning...
November 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27646474/irgd-mediated-core-shell-nanoparticles-loading-carmustine-and-o-6-benzylguanine-for-glioma-therapy
#10
Chang Liu, Sen Yao, Xuqian Li, Feng Wang, Yanyan Jiang
iRGD (internalizing RGD) with high affinity to αν integrins was reported to enhance tumor penetrability by binding to neuropilin-1 (NRP-1). Based on our previous study, chitosan surface-modified poly (lactide-co-glycolides) nanoparticles (PLGA/CS NPs), loaded with carmustine (BCNU) and its sensitizer (O(6)-benzylguanine, BG) showed stronger anti-tumor effect than free drugs. In present study, PLGA/CS NPs (NPs) with core-shell structure were prepared and modified with iRGD or mPEG. F98, C6 or U87 cell lines with different receptors levels were selected for in vitro and in vivo studies...
October 6, 2016: Journal of Drug Targeting
https://www.readbyqxmd.com/read/27620713/decitabine-prior-to-salvaged-unrelated-cord-blood-transplantation-for-refractory-or-relapsed-childhood-acute-leukemia
#11
Haixia Zhou, Changcheng Zheng, Xiaoyu Zhu, Baolin Tang, Juan Tong, Xuhan Zhang, Lei Zhang, Huilan Liu, Zimin Sun
No clinical studies have investigated the role of decitabine as a part of the myeloablative conditioning regimen prior to UCBT for refractory or relapsed childhood AL in patients in NR status. The aim of this study was to identify the potential benefits of decitabine as a prior therapy before salvaged unrelated UCBT for refractory or relapsed childhood AL. Eight consecutive patients with childhood refractory/relapsed AL were enrolled in our study between 2013 and 2014. All patients were in NR status before the time of transplant and had features associated with poor outcomes, such as CNSL, MDS-AML, high WBC count at diagnosis, and hypodiploid status (FLT3+/ITD+)...
September 12, 2016: Pediatric Transplantation
https://www.readbyqxmd.com/read/27614867/infusion-reactions-are-common-after-high-dose-carmustine-in-beam-chemotherapy-and-are-not-reduced-by-lengthening-the-time-of-administration
#12
Sarah Perreault, Julie Baker, Erin Medoff, Kathryn Pratt, Francine Foss, Iris Isufi, Stuart Seropian, Dennis L Cooper
PURPOSE: Carmustine (BCNU) is used in the conditioning regimens BEAM and CBV for autologous stem cell transplantation. Carmustine-related infusion reactions, while not described in the BEAM literature, occurred in 95 % of patients who received CBV. The most common symptoms include flushing, facial pain, headache, and hypotension. These reactions have been attributed to the absolute ethanol that is used in the reconstitution process or alternatively by a direct effect of carmustine. It is currently recommended that carmustine 300 mg/m(2) be infused over at least 100 min (3-5 mg/m(2)/min)...
January 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27601895/1-3-bis-2-chloroethyl-1-nitrosourea-loaded-bovine-serum-albumin-nanoparticles-with-dual-magnetic-resonance-fluorescence-imaging-for-tracking-of-chemotherapeutic-agents
#13
Kuo-Chen Wei, Feng-Wei Lin, Chiung-Yin Huang, Chen-Chi M Ma, Ju-Yu Chen, Li-Ying Feng, Hung-Wei Yang
To date, knowing how to identify the location of chemotherapeutic agents in the human body after injection is still a challenge. Therefore, it is urgent to develop a drug delivery system with molecular imaging tracking ability to accurately understand the distribution, location, and concentration of a drug in living organisms. In this study, we developed bovine serum albumin (BSA)-based nanoparticles (NPs) with dual magnetic resonance (MR) and fluorescence imaging modalities (fluorescein isothiocyanate [FITC]-BSA-Gd/1,3-bis(2-chloroethyl)-1-nitrosourea [BCNU] NPs) to deliver BCNU for inhibition of brain tumor cells (MBR 261-2)...
2016: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/27466824/t7-peptide-functionalized-peg-plga-micelles-loaded-with-carmustine-for-targeting-therapy-of-glioma
#14
Yunke Bi, Lisha Liu, Yifei Lu, Tao Sun, Chen Shen, Xinli Chen, Qinjun Chen, Sai An, Xi He, Chunhui Ruan, Yinhao Wu, Yujie Zhang, Qin Guo, Zhixing Zheng, Yaohua Liu, Meiqing Lou, Shiguang Zhao, Chen Jiang
Glioma is regarded as the deadliest and most common brain tumor because of the extremely difficult surgical excision ascribed from its invasive nature. In addition, the natural blood-brain barrier (BBB) greatly restricts the therapeutics' penetration into the central nervous system. Carmustine (BCNU) is a widely used antiglioma drug in clinical applications. However, its serious complications prevent it from being applied in a clinical setting to some extent. Thus, it is urgent to explore novel BCNU delivery systems specially designed for glioma...
October 4, 2016: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/27459746/-long-term-efficacy-of-bcnu-wafers-for-malignant-gliomas
#15
Yoshiki Arakawa
No abstract text is available yet for this article.
June 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27453265/synthesis-sar-and-biological-evaluation-of-a-novel-series-of-1-2-chloroethyl-1-nitroso-3-2-3-oxobenzoelenazol-2-3h-yl-ethyl-urea-organoselenium-compounds-for-cancer-therapy
#16
S Ye, X Zheng, T Hu, H Zeng
Thioredoxin reductase 1 (TrxR1) is an important potential anticancer drug target and closely related to both carcinogenesis and cancer progression. Ethaselen (BBSKE), a novel organoselenium compound inhibiting TrxR1 with selective antitumor effect, while its symmetrical structure results in poor solubility. Carmustine (BCNU), a DNA cross-link agent and also a deactivator of TrxR, is with high toxicity and low selectivity which limit its clinical application to some extents. Herein, a novel compound, 1-(2-chloroethyl)-1-nitroso-3-(2-(3-oxobenzoelenazol-2(3H)-yl)ethyl)urea(4a-1), which was designed through the combination of Ethaselen and Carmustine, showed good solubility, good tagetability, low toxicity and excellent antitumor activity by synergism...
June 30, 2016: Cellular and Molecular Biology
https://www.readbyqxmd.com/read/27452129/quantitative-analysis-of-brain-edema-in-patients-with-malignant-glioma-treated-with-bcnu-wafers
#17
Satoshi Murai, Tomotsugu Ichikawa, Kazuhiko Kurozumi, Yosuke Shimazu, Tetsuo Oka, Yoshihiro Otani, Toshihiko Shimizu, Isao Date
BCNU wafers are a form of interstitial chemotherapy that is expected to improve the survival of patients with malignant glioma. However, their adverse events, especially brain edema, sometimes cause significant clinical symptoms. In this study, we performed a volumetric analysis of brain edema after the implantation of BCNU wafers and reported on the clinical course, and exacerbation factors of brain edema. Twelve patients who underwent surgical resection of supratentorial malignant glioma and BCNU wafer implantation, were enrolled...
November 2016: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/27379495/pre-radiation-chemotherapy-improves-survival-in-pediatric-diffuse-intrinsic-pontine-gliomas
#18
Z Gokce-Samar, P A Beuriat, C Faure-Conter, C Carrie, S Chabaud, L Claude, F Di Rocco, C Mottolese, A Szathmari, C Chabert, D Frappaz
BACKGROUND: The median survival of patients with diffuse intrinsic pontine glioma (DIPG) remains less than 1 year. The BSG 98 pre-irradiation chemotherapy protocol showed a significant increase in overall survival. In contrast to current treatment strategies, patients did not have to undergo surgical stereotactic biopsy, which can sometimes lead to complications, to be included in this protocol. MATERIALS AND METHODS: We retrospectively reviewed all the cases of DIPG that were treated in our department from September 15, 2004 to September 15, 2014...
August 2016: Child's Nervous System: ChNS: Official Journal of the International Society for Pediatric Neurosurgery
https://www.readbyqxmd.com/read/27365141/retrospective-evaluation-of-the-meam-regimen-as-a-conditioning-regimen-before-autologous-peripheral-blood-stem-cell-transplantation-for-lymphoma-in-two-centers-with-different-dosing-schedules-of-melphalan
#19
Miyuki Sugimoto, Shoko Ito, Kiyomi Mashima, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Ryoko Yamasaki, Yasufumi Kawasaki, Masahiro Ashizawa, Chihiro Yamamoto, Shin-Ichiro Fujiwara, Kiyoshi Okazuka, Kaoru Hatano, Kazuya Sato, Iekuni Oh, Ken Ohmine, Takahiro Suzuki, Kazuo Muroi, Shinichi Kako, Yoshinobu Kanda
The BEAM regimen consisting of carmustine (BCNU), etoposide, cytarabine, and melphalan (MEL) is widely used before autologous hematopoietic stem cell transplantation (auto-HSCT) for lymphoma. However, intravenous BCNU is not available in Japan, and therefore, ranimustine (MCNU) has been used instead of BCNU (the MEAM regimen). We retrospectively analyzed the outcome of 79 adult patients who underwent auto-HSCT for lymphoma using this regimen in two centers, with 1- and 2-day dosing of MEL, respectively. Three-year overall survival (OS) and progression-free survival (PFS) probabilities were 77...
September 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27355941/resistance-to-dna-damaging-agents-produced-invasive-phenotype-of-rat-glioma-cells-characterization-of-a-new-in-vivo-model
#20
Sonja Stojković, Ana Podolski-Renić, Jelena Dinić, Željko Pavković, Jose M Ayuso, Luis J Fernández, Ignacio Ochoa, Victor M Pérez-García, Vesna Pešić, Milica Pešić
Chemoresistance and invasion properties are severe limitations to efficient glioma therapy. Therefore, development of glioma in vivo models that more accurately resemble the situation observed in patients emerges. Previously, we established RC6 rat glioma cell line resistant to DNA damaging agents including antiglioma approved therapies such as 3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and temozolomide (TMZ). Herein, we evaluated the invasiveness of RC6 cells in vitro and in a new orthotopic animal model. For comparison, we used C6 cells from which RC6 cells originated...
2016: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
keyword
keyword
54805
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"